GIBSON DUNN

Gibson Dunn Advises Shattuck Labs on Private Placement of Up to Approximately $103 Million

Firm News | August 5, 2025

Gibson Dunn is representing Shattuck Labs, Inc. in connection with a private placement of securities expected to generate aggregate gross proceeds of up to approximately $103 million to a syndicate of healthcare investors led by OrbiMed, including a large, healthcare-dedicated fund, Coastlands Capital, Prosight Capital, Adage Capital, Redmile Group, and NextBio Capital.

Shattuck Labs, Inc. is a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor superfamily receptors for the treatment of patients with inflammatory and immune-related diseases. Shattuck has offices in both Austin, Texas and Durham, North Carolina.

Gibson Dunn regularly advises life sciences companies and healthcare investors on private placements and capital markets transactions in the biotechnology sector.

The Gibson Dunn team included Ryan Murr, Branden Berns, Melanie Neary, Candice Johnson, Jasmine Vitug, and Anika Gidwani.

Related Capabilities

Capital Markets

Life Sciences

Related People

Ryan A. Murr

Branden C. Berns

Melanie E. Neary

Candice D. Johnson

Jasmine L. Vitug

Anika Gidwani

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**